Agammaglobulinemia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management

Endocr Metab Immune Disord Drug Targets. 2020;20(9):1434-1447. doi: 10.2174/1871530320666200508114349.

Abstract

Agammaglobulinemia is a type of primary antibody deficiencies, characterized by severe reduction in serum level of all types of immunoglobulins level and absence of B cells in the peripheral blood. X-linked and various autosomal recessive/dominant mutations have been identified underlying the pathogenesis of this disorder. Affected patients present a broad range of clinical manifestations, including respiratory infections, gastrointestinal complications, Enterovirus infections, autoimmunity, and malignancies. This disease can be controlled by different therapeutic strategies. In this review, we describe different aspects of agammaglobulinemia such as epidemiology, pathogenesis, clinical phenotype, diagnosis, management, and prognosis of congenital agammaglobulinemia.

Keywords: Primary immunodeficiency; agammaglobulinemia; clinical phenotype; diagnosis; epidemiology; management; pathogenesis; prognosis.

Publication types

  • Review

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase / genetics
  • Agammaglobulinemia / diagnosis*
  • Agammaglobulinemia / epidemiology*
  • Agammaglobulinemia / genetics
  • Agammaglobulinemia / therapy
  • Animals
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / physiology
  • Disease Management*
  • Humans
  • Immunoglobulins / administration & dosage
  • Mutation / genetics
  • Phenotype*
  • Prognosis
  • Respiratory Tract Infections / diagnosis
  • Respiratory Tract Infections / epidemiology
  • Respiratory Tract Infections / genetics
  • Respiratory Tract Infections / therapy

Substances

  • Immunoglobulins
  • Agammaglobulinaemia Tyrosine Kinase
  • BTK protein, human